These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 24480844

  • 1. Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty.
    Verdoia M, Secco GG, Cassetti E, Schaffer A, Barbieri L, Perrone-Filardi P, Marino P, Suryapranata H, Sinigaglia F, De Luca G.
    Blood Coagul Fibrinolysis; 2014 Mar; 25(2):107-13. PubMed ID: 24480844
    [Abstract] [Full Text] [Related]

  • 2. Platelet HPA-1 a/HPA-1 b polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI.
    Verdoia M, Secco GG, Barbieri L, Cassetti E, Schaffer A, Sinigaglia F, Marino P, Suryapranata H, De Luca G, Novara Atherosreclerosis Study Group (NAS).
    Platelets; 2014 Mar; 25(5):367-72. PubMed ID: 24283589
    [Abstract] [Full Text] [Related]

  • 3. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban.
    Verdoia M, Pergolini P, Barbieri L, Rolla R, Nardin M, Negro F, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS).
    Thromb Res; 2018 Apr; 164():17-23. PubMed ID: 29475177
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mean platelet volume and the risk of periprocedural myocardial infarction in patients undergoing coronary angioplasty.
    Verdoia M, Camaro C, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G.
    Atherosclerosis; 2013 May; 228(1):136-41. PubMed ID: 23518179
    [Abstract] [Full Text] [Related]

  • 6. MTHFR polymorphism and risk of periprocedural myocardial infarction after coronary stenting.
    Verdoia M, Schaffer A, Cassetti E, Barbieri L, Di Giovine G, Marino P, De Luca G, Novara Atherosclerosis Study Group (NAS).
    Nutr Metab Cardiovasc Dis; 2014 May; 24(5):532-7. PubMed ID: 24418373
    [Abstract] [Full Text] [Related]

  • 7. Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting.
    Verdoia M, Schaffer A, Barbieri L, Cassetti E, Di Giovine G, Marino P, De Luca G, Novara Atherosclerosis Study Group (NAS).
    J Cardiovasc Med (Hagerstown); 2015 Feb; 16(2):100-5. PubMed ID: 24625566
    [Abstract] [Full Text] [Related]

  • 8. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry.
    Lindsey JB, Marso SP, Pencina M, Stolker JM, Kennedy KF, Rihal C, Barsness G, Piana RN, Goldberg SL, Cutlip DE, Kleiman NS, Cohen DJ, EVENT Registry Investigators.
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1074-82. PubMed ID: 19926047
    [Abstract] [Full Text] [Related]

  • 9. [Polymorphism of GPIIIA platelet glycoprotein gene PIA1/A2 compared to plasma hemostasis in myocardial infarction patients].
    Tereshchenko SN, Levchuk NN, Drozdov VN, Shaĭkhaev GO, Leont'ev SG, Kirienko AI, Moiseev VS.
    Ter Arkh; 1999 Nov; 71(9):66-70. PubMed ID: 10553630
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Prasad A, Gersh BJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Pocock SJ, McLaurin BT, Cox DA, Lansky AJ, Mehran R, Stone GW.
    J Am Coll Cardiol; 2009 Jul 28; 54(5):477-86. PubMed ID: 19628125
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitors.
    De Luca G, Gibson MC, Hof AW, Cutlip D, Zeymer U, Noc M, Maioli M, Zorman S, Gabriel MH, Secco GG, Emre A, Dudek D, Rakowski T, Gyongyosi M, Huber K, Bellandi F, EGYPT cooperation.
    J Cardiovasc Med (Hagerstown); 2013 Nov 28; 14(11):815-20. PubMed ID: 23519096
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Goto K, Lansky AJ, Nikolsky E, Fahy M, Feit F, Ohman EM, White HD, Mehran R, Bertrand ME, Desmet W, Hamon M, Stone GW.
    JACC Cardiovasc Interv; 2011 Jul 28; 4(7):769-77. PubMed ID: 21777885
    [Abstract] [Full Text] [Related]

  • 14. High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention.
    Sattler KJ, Herrmann J, Yün S, Lehmann N, Wang Z, Heusch G, Sack S, Erbel R, Levkau B.
    Eur Heart J; 2009 Aug 28; 30(15):1894-902. PubMed ID: 19474052
    [Abstract] [Full Text] [Related]

  • 15. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Laine M, Toesca R, Berbis J, Frere C, Barnay P, Pansieri M, Peyre JP, Michelet P, Bessereau J, Camilleri E, Helaf O, Camaleonte M, Paganelli F, Dignat-George F, Bonello L.
    Thromb Res; 2013 Jul 28; 132(1):e15-8. PubMed ID: 23726090
    [Abstract] [Full Text] [Related]

  • 16. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, Bali L, Lambert M, Alessi MC, Bonnet JL.
    Thromb Haemost; 2007 Feb 28; 97(2):282-7. PubMed ID: 17264958
    [Abstract] [Full Text] [Related]

  • 17. Impact of the Polymorphism rs5751876 of the Purinergic Receptor ADORA2A on Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention.
    Negro F, Verdoia M, Nardin M, Suryapranata H, Kedhi E, Dudek D, De Luca G, Novara Atherosclerosis Study Group (NAS).
    J Atheroscler Thromb; 2021 Feb 01; 28(2):137-145. PubMed ID: 33342966
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction.
    Bonello L, Berbis J, Laine M, Armero S, Bessereau J, Jacquin L, Bonello C, Camillieri E, Barragan P, Dignat-George F, Paganelli F, Camoin-Jau L.
    Thromb Haemost; 2012 Jul 01; 108(1):101-6. PubMed ID: 22535315
    [Abstract] [Full Text] [Related]

  • 20. Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the CUSTOMIZE Registry).
    Caggegi A, Capodanno D, Capranzano P, Chisari A, Ministeri M, Mangiameli A, Ronsivalle G, Ricca G, Barrano G, Monaco S, Di Salvo ME, Tamburino C.
    Am J Cardiol; 2011 Aug 01; 108(3):355-9. PubMed ID: 21545992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.